

# Fabien Praz

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/198860/publications.pdf>

Version: 2024-02-01

188  
papers

8,758  
citations

81900

39  
h-index

53230

85  
g-index

199  
all docs

199  
docs citations

199  
times ranked

5663  
citing authors

#	ARTICLE	IF	CITATIONS
1	Surgical versus transcatheter repair for secondary mitral regurgitation: A propensity score-matched cohorts comparison. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2023, 165, 2037-2046.e4.	0.8	15
2	Systemic Corticosteroid Exposure and Atrioventricular Conductance Delays After Transcatheter Aortic Valve Implantation. <i>Cardiovascular Revascularization Medicine</i> , 2022, 37, 1-6.	0.8	2
3	2021 ESC/EACTS Guidelines for the management of valvular heart disease. <i>European Heart Journal</i> , 2022, 43, 561-632.	2.2	2,169
4	Conservative, surgical, and percutaneous treatment for mitral regurgitation shortly after acute myocardial infarction. <i>European Heart Journal</i> , 2022, 43, 641-650.	2.2	36
5	Clinical impact of left atrial appendage filling defects in patients undergoing transcatheter aortic valve implantation. <i>European Heart Journal Cardiovascular Imaging</i> , 2022, 23, 1354-1364.	1.2	2
6	Anatomical and Technical Predictors of Three-Dimensional Mitral Valve Area Reduction After Transcatheter Edge-To-Edge Repair. <i>Journal of the American Society of Echocardiography</i> , 2022, 35, 96-104.	2.8	13
7	Clinical outcomes following transcatheter aortic valve implantation in patients with porcelain aorta. <i>Journal of Cardiovascular Computed Tomography</i> , 2022, 16, 215-221.	1.3	4
8	Sinus of Valsalva Dimension and Clinical Outcomes in Patients Undergoing Transcatheter Aortic Valve Implantation. <i>American Heart Journal</i> , 2022, 244, 94-106.	2.7	8
9	Validation of the VARC-3 Technical Success Definition in Patients Undergoing TAVR. <i>JACC: Cardiovascular Interventions</i> , 2022, 15, 353-364.	2.9	11
10	Electrosurgical Laceration and Stabilization of MitraClip Followed by Valve Implantation for Iatrogenic Mitral Stenosis. <i>JACC: Cardiovascular Interventions</i> , 2022, 15, 110-112.	2.9	4
11	Transcatheter Edge-to-Edge Repair Gives Years to Life and Life to Years to Elderly Patients With Secondary Mitral Regurgitation. <i>JACC: Cardiovascular Interventions</i> , 2022, , .	2.9	1
12	Transapical mitral valve implantation for treatment of symptomatic mitral valve disease: a real-world multicentre experience. <i>European Journal of Heart Failure</i> , 2022, 24, 899-907.	7.1	33
13	2021 ESC/EACTS Guidelines for the management of valvular heart disease. <i>EuroIntervention</i> , 2022, 17, e1126-e1196.	3.2	161
14	Right Ventricular-Pulmonary Arterial Coupling and Afterload Reserve in Patients Undergoing Transcatheter Tricuspid Valve Repair. <i>Journal of the American College of Cardiology</i> , 2022, 79, 448-461.	2.8	96
15	Acute coronary syndromes in young patients: Phenotypes, causes and clinical outcomes following percutaneous coronary interventions.. <i>International Journal of Cardiology</i> , 2022, 350, 1-8.	1.7	5
16	Frequency and Outcomes of Periprocedural MI in Patients With Chronic Coronary Syndromes Undergoing PCI. <i>Journal of the American College of Cardiology</i> , 2022, 79, 513-526.	2.8	24
17	Management and Outcome of Failed Percutaneous Edge-to-Edge Mitral Valve Plasty. <i>JACC: Cardiovascular Interventions</i> , 2022, 15, 411-422.	2.9	7
18	Cardiovascular outcomes in patients with left atrial enlargement undergoing transcatheter aortic valve implantation. <i>Catheterization and Cardiovascular Interventions</i> , 2022, , .	1.7	1

#	ARTICLE	IF	CITATIONS
19	Impact of First-Phase Ejection Fraction on Clinical Outcomes in Patients Undergoing Transcatheter Aortic Valve Implantation. <i>Cardiovascular Revascularization Medicine</i> , 2022, 42, 55-61.	0.8	2
20	Transcatheter aortic valve implantation in patients with rheumatic aortic stenosis. <i>Heart</i> , 2022, 108, 1225-1233.	2.9	3
21	Early Clinical Experience With the TRICENTO Bicaval Valved Stent for Treatment of Symptomatic Severe Tricuspid Regurgitation: A Multicenter Registry. <i>Circulation: Cardiovascular Interventions</i> , 2022, 15, CIRCINTERVENTIONS121011302.	3.9	17
22	Characteristics and outcomes of patients screened for transcatheter mitral valve implantation: <sc>1-year</sc> results from the <sc>CHOICEâ€MI</sc> registry. <i>European Journal of Heart Failure</i> , 2022, 24, 887-898.	7.1	32
23	Diagnostic performance of quantitative coronary artery disease assessment using computed tomography in patients with aortic stenosis undergoing transcatheter aortic-valve implantation. <i>BMC Cardiovascular Disorders</i> , 2022, 22, 178.	1.7	6
24	Five-year outcomes of mild paravalvular regurgitation after transcatheter aortic valve implantation. <i>EuroIntervention</i> , 2022, 18, 33-42.	3.2	42
25	Reply: The time has come to use attitudinally appropriate terminology when describing cardiac anatomy. <i>EuroIntervention</i> , 2022, 17, 1539-1540.	3.2	0
26	Assessment of New Onset Arrhythmias After Transcatheter Aortic Valve Implantation Using an Implantable Cardiac Monitor. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, .	2.4	2
27	Imaging-Based, Patient-Specific Three-Dimensional Printing to Plan, Train, and Guide Cardiovascular Interventions: A Systematic Review and Meta-Analysis. <i>Heart Lung and Circulation</i> , 2022, 31, 1203-1218.	0.4	8
28	Percutaneous Tricuspid Valve Repair. <i>Reviews in Cardiovascular Medicine</i> , 2022, 23, 220.	1.4	2
29	Caval Valve Implantation for Advanced Tricuspid Regurgitation. <i>JACC: Cardiovascular Interventions</i> , 2022, 15, 1378-1381.	2.9	1
30	Transcatheter Mitral Valve Repair in Patients With Atrial Functional Mitral Regurgitation. <i>JACC: Cardiovascular Imaging</i> , 2022, 15, 1843-1851.	5.3	33
31	Risk and Timing of Noncardiac Surgery After Transcatheter Aortic Valve Implantation. <i>JAMA Network Open</i> , 2022, 5, e2220689.	5.9	4
32	Multicenter Experience With the Transcatheter Leaflet Repair System for Symptomatic Tricuspid Regurgitation. <i>JACC: Cardiovascular Interventions</i> , 2022, 15, 1352-1363.	2.9	22
33	Clinical impact of mitral calcium volume in patients undergoing transcatheter aortic valve implantation. <i>Journal of Cardiovascular Computed Tomography</i> , 2021, 15, 356-365.	1.3	20
34	Impact of Proportionality of Secondary Mitral Regurgitation on Outcome After Transcatheter Mitral Valve Repair. <i>JACC: Cardiovascular Imaging</i> , 2021, 14, 715-725.	5.3	42
35	Synergistic Effect of 2 Transcatheter Tricuspid Valve Treatment Modalities. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, e5-e7.	2.9	0
36	Discharge Location and Outcomes After Transcatheter Aortic Valve Implantation. <i>American Journal of Cardiology</i> , 2021, 140, 95-102.	1.6	2

#	ARTICLE	IF	CITATIONS
37	Deferred versus Expedited Aortic Valve Replacement in Patients with Symptomatic Severe Aortic Stenosis During the SARS-CoV-2 Pandemic (AS DEFER): A Research Letter. <i>Global Heart</i> , 2021, 16, 32.	2.3	3
38	Functional assessment of myocardial ischaemia by intracoronary ECG. <i>Open Heart</i> , 2021, 8, e001447.	2.3	4
39	True-severe stenosis in paradoxical low-flow low-gradient aortic stenosis: outcomes after transcatheter aortic valve replacement. <i>European Heart Journal Quality of Care &amp; Clinical Outcomes</i> , 2021, 7, 366-377.	4.0	4
40	Transcatheter tricuspid valve treatment: does annular reduction make a difference?. <i>EuroIntervention</i> , 2021, 16, e1213-e1214.	3.2	1
41	Transcatheter Tricuspid Valve Intervention in Patients With Right Ventricular Dysfunction or Pulmonary Hypertension. <i>Circulation: Cardiovascular Interventions</i> , 2021, 14, e009685.	3.9	26
42	The role of transcatheter mitral valve leaflet approximation for the treatment of secondary mitral regurgitation: current status and future prospects. <i>Expert Review of Medical Devices</i> , 2021, 18, 261-272.	2.8	1
43	Plaque erosion causing ST-elevation myocardial infarction after consumption of cannabis and N2O in a 27-year old man: a case report. <i>BMC Cardiovascular Disorders</i> , 2021, 21, 147.	1.7	5
44	Impact of effective regurgitant orifice area on outcome of secondary mitral regurgitation transcatheter repair. <i>Clinical Research in Cardiology</i> , 2021, 110, 732-739.	3.3	8
45	The management of secondary mitral regurgitation in patients with heart failure: a joint position statement from the Heart Failure Association (HFA), European Association of Cardiovascular Imaging (EACVI), European Heart Rhythm Association (EHRA), and European Association of Percutaneous Cardiovascular Interventions (EAPCI) of the ESC. <i>European Heart Journal</i> , 2021, 42, 1254-1269.	2.2	78
46	Transcatheter Mitral Valve Replacement for Mitral Valve-in-Valve, Valve-in-Ring, and Valve-in-MAC Using Balloon-Expandable Transcatheter Heart Valves. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 873-878.	2.9	4
47	Staging cardiac damage associated with aortic stenosis in patients undergoing transcatheter aortic valve implantation. <i>IJC Heart and Vasculature</i> , 2021, 33, 100768.	1.1	8
48	Impact of Right Ventricular Dysfunction on Outcomes After Transcatheter Edge-to-Edge Repair for Secondary Mitral Regurgitation. <i>JACC: Cardiovascular Imaging</i> , 2021, 14, 768-778.	5.3	65
49	Heart valve sizing and clinical outcomes in patients undergoing transcatheter aortic valve implantation. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 98, E768-E779.	1.7	7
50	Sex-Related Clinical Characteristics and Outcomes of Patients Undergoing Transcatheter Edge-to-Edge Repair for Secondary Mitral Regurgitation. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 819-827.	2.9	24
51	Safety and Feasibility of MitraClip Implantation in Patients with Acute Mitral Regurgitation after Recent Myocardial Infarction and Severe Left Ventricle Dysfunction. <i>Journal of Clinical Medicine</i> , 2021, 10, 1819.	2.4	6
52	Validation of the 2019 Expert Consensus Algorithm for the Management of Conduction Disturbances After TAVR. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 981-991.	2.9	14
53	Hemolysis After Transcatheter Mitral Valve Implantation Resolved by Valve Retensioning. <i>JACC: Case Reports</i> , 2021, 3, 864-870.	0.6	4
54	Refined staging classification of cardiac damage associated with aortic stenosis and outcomes after transcatheter aortic valve implantation. <i>European Heart Journal Quality of Care &amp; Clinical Outcomes</i> , 2021, 7, 532-541.	4.0	22

#	ARTICLE	IF	CITATIONS
55	Impact of Residual Mitral Regurgitation on Survival After Transcatheter Edge-to-Edge Repair for Secondary Mitral Regurgitation. JACC: Cardiovascular Interventions, 2021, 14, 1243-1253.	2.9	39
56	Sex-Based Differences in Bleeding Risk After Percutaneous Coronary Intervention and Implications for the Academic Research Consortium High Bleeding Risk Criteria. Journal of the American Heart Association, 2021, 10, e021965.	3.7	23
57	Outcomes of transcatheter tricuspid valve intervention by right ventricular function: a multicentre propensity-matched analysis. EuroIntervention, 2021, 17, e343-e352.	3.2	41
58	Transcatheter Tricuspid Valve Intervention in Patients With Previous Left Valve Surgery. Canadian Journal of Cardiology, 2021, 37, 1094-1102.	1.7	4
59	2021 ESC/EACTS Guidelines for the management of valvular heart disease. European Journal of Cardio-thoracic Surgery, 2021, 60, 727-800.	1.4	344
60	Integrative echocardiographic assessment of patients with secondary mitral regurgitation undergoing transcatheter edge-to-edge repair. Catheterization and Cardiovascular Interventions, 2021, 98, 1404-1412.	1.7	1
61	Permanent pacemaker implantation late after transcatheter aortic valve implantation. Heart Rhythm, 2021, 18, 2033-2039.	0.7	11
62	Learning From Failure at the CUTTING-EDGE of Transcatheter Mitral Valve Therapies. JACC: Cardiovascular Interventions, 2021, 14, 2022-2026.	2.9	0
63	Potential Candidates for Transcatheter Tricuspid Valve Intervention After Transcatheter Aortic Valve Replacement. JACC: Cardiovascular Interventions, 2021, 14, 2246-2256.	2.9	20
64	Deep learning-based prediction of early cerebrovascular events after transcatheter aortic valve replacement. Scientific Reports, 2021, 11, 18754.	3.3	8
65	The ten commandments for the 2021 ESC/EACTS Guidelines on valvular heart disease. European Heart Journal, 2021, 42, 4207-4208.	2.2	106
66	Impact of clinical presentation on bleeding risk after percutaneous coronary intervention and implications for the ARC-HBR definition. EuroIntervention, 2021, 17, e898-e909.	3.2	45
67	Retrograde Retrieval of a Novel Large Mitral Clip After Embolization Into the Left Ventricle. JACC: Case Reports, 2021, 3, 1561-1568.	0.6	4
68	Multimodality Imaging for Evaluation of Bicaval Valved Stent Implantation in Severe Tricuspid Regurgitation. JACC: Case Reports, 2021, 3, 1512-1518.	0.6	0
69	OUP accepted manuscript. European Journal of Cardio-thoracic Surgery, 2021, , .	1.4	2
70	Effect of Timing of Staged Percutaneous Coronary Intervention on Clinical Outcomes in Patients With Acute Coronary Syndromes. Journal of the American Heart Association, 2021, 10, e023129.	3.7	2
71	Transcatheter treatment for tricuspid valve disease. EuroIntervention, 2021, 17, 791-808.	3.2	136
72	Outcomes Stratified by Adapted Inclusion Criteria After Mitral Edge-to-Edge Repair. Journal of the American College of Cardiology, 2021, 78, 2408-2421.	2.8	34

#	ARTICLE	IF	CITATIONS
73	630â€fImpact of right ventricular dysfunction after mitraclip treatment as a bridge to heart transplantation: insight from the mitrbridge strategy. European Heart Journal Supplements, 2021, 23, .	0.1	0
74	Does isolated mitral annular calcification in the absence of mitral valve disease affect clinical outcomes after transcatheter aortic valve replacement?. European Heart Journal Cardiovascular Imaging, 2020, 21, 522-532.	1.2	28
75	An unusual cause of recurrent mitral regurgitation after percutaneous mitral valve repair. Catheterization and Cardiovascular Interventions, 2020, 96, E393-E394.	1.7	0
76	A New Age for Transcatheter Mitral Valve Repair. JACC: Cardiovascular Interventions, 2020, 13, 2415-2417.	2.9	11
77	MitraClip in secondary mitral regurgitation as a bridge to heart transplantation: 1-year outcomes from the International MitraBridge Registry. Journal of Heart and Lung Transplantation, 2020, 39, 1353-1362.	0.6	75
78	Validation of high bleeding risk criteria and definition as proposed by the academic research consortium for high bleeding risk. European Heart Journal, 2020, 41, 3743-3749.	2.2	89
79	Adding a Clasp to the Toolbox for Transcatheter Mitral Valve Repair. JACC: Cardiovascular Interventions, 2020, 13, 2358-2360.	2.9	0
80	Editorial: Percutaneous Mitral Valve Interventions (Repair): Current Indications and Future Perspectives. Frontiers in Cardiovascular Medicine, 2020, 7, 581109.	2.4	0
81	Impact of Left Ventricular Outflow Tract Calcification on Procedural Outcomes After Transcatheter Aortic Valve Replacement. JACC: Cardiovascular Interventions, 2020, 13, 1789-1799.	2.9	66
82	Optimal Fluoroscopic Projections of Coronary Ostia and Bifurcations Defined by Computed Tomographic Coronary Angiography. JACC: Cardiovascular Interventions, 2020, 13, 2560-2570.	2.9	28
83	Prosthesisâ€Patient Mismatch Based on Energy Loss Index After Transcatheter Aortic Valve Replacement. JACC: Cardiovascular Interventions, 2020, 13, 2584-2586.	2.9	4
84	Reply. JACC: Cardiovascular Interventions, 2020, 13, 2446-2447.	2.9	1
85	Impact of Massive or Torrential Tricuspid Regurgitation in Patients Undergoing Transcatheter Tricuspid Valve Intervention. JACC: Cardiovascular Interventions, 2020, 13, 1999-2009.	2.9	42
86	Valvular and Nonvalvular Atrialâ€Fibrillation in Patients Undergoing Transcatheter Aortic Valve Replacement. JACC: Cardiovascular Interventions, 2020, 13, 2124-2133.	2.9	18
87	Imaging and Patient Selection for Transcatheter Tricuspid Valve Interventions. Frontiers in Cardiovascular Medicine, 2020, 7, 60.	2.4	20
88	Mitral and Tricuspid Transcatheter Interventions Current Indications and Future Directions. Frontiers in Cardiovascular Medicine, 2020, 7, 61.	2.4	8
89	The PASCAL Deviceâ€Early Experience with a Leaflet Approximation Device: What Are the Benefits/Limitations Compared with the MitraClip?. Current Cardiology Reports, 2020, 22, 74.	2.9	16
90	Transcatheter Aortic Valve Replacement in Patients With Multivalvular Heart Disease. JACC: Cardiovascular Interventions, 2020, 13, 1503-1514.	2.9	38

#	ARTICLE	IF	CITATIONS
91	Outcomes of TTVI in Patients With Pacemaker or Defibrillator Leads. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 554-564.	2.9	32
92	Hemodynamic Relevance of Anomalous Coronary Arteries Originating From the Opposite Sinus of Valsalva-In Search of the Evidence. <i>Frontiers in Cardiovascular Medicine</i> , 2020, 7, 591326.	2.4	42
93	Validation of the Academic Research Consortium for High Bleeding Risk (ARC-HBR) criteria in patients undergoing percutaneous coronary intervention and comparison with contemporary bleeding risk scores. <i>EuroIntervention</i> , 2020, 16, 371-379.	3.2	132
94	Transcatheter treatment of multivalvular heart disease. <i>EuroIntervention</i> , 2020, 16, 858-859.	3.2	0
95	Long-Term Outcomes of the FORMA Transcatheter Tricuspid Valve Repair System for the Treatment of Severe Tricuspid Regurgitation. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 1438-1447.	2.9	44
96	Case report of simultaneous transcatheter mitral valve-in-valve implantation and percutaneous closure of two paravalvular leaks. <i>European Heart Journal - Case Reports</i> , 2019, 3, ytz123.	0.6	5
97	Everolimus-Eluting Biodegradable Polymer Versus Everolimus-Eluting Durable Polymer Stent for Coronary Revascularization in Routine Clinical Practice. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 1665-1675.	2.9	23
98	PASCAL. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 1379-1381.	2.9	6
99	Surgical Transatrial Implantation of Transcatheter Heart Valves in Severe Mitral Annular Calcification. <i>Interventional Cardiology Clinics</i> , 2019, 8, 313-319.	0.4	4
100	Percutaneous Mitral Edge-to-Edge Repair: State of the Art and a Glimpse to the Future. <i>Frontiers in Cardiovascular Medicine</i> , 2019, 6, 122.	2.4	14
101	Prognostic Relevance of Left Ventricular Myocardial Performance After Transcatheter Aortic Valve Replacement. <i>Circulation: Cardiovascular Interventions</i> , 2019, 12, e006612.	3.9	4
102	Transcatheter Versus Medical Treatment of Patients With Symptomatic Severe Tricuspid Regurgitation. <i>Journal of the American College of Cardiology</i> , 2019, 74, 2998-3008.	2.8	302
103	Prosthesis-Patient Mismatch Following Transcatheter Aortic Valve Replacement With Supra-Annular and Intra-Annular Prostheses. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 2173-2182.	2.9	60
104	TCT-753 Prosthesis-Patient Mismatch Following Transcatheter Aortic Valve Replacement With Supra-Annular and Intra-Annular Prosthesis. <i>Journal of the American College of Cardiology</i> , 2019, 74, B739.	2.8	0
105	Imaging in patients with severe mitral annular calcification: insights from a multicentre experience using transatrial balloon-expandable valve replacement. <i>European Heart Journal Cardiovascular Imaging</i> , 2019, 20, 1395-1406.	1.2	13
106	Incidence and outcome of peri-procedural transcatheter heart valve embolization and migration: the TRAVEL registry (TranscatheteR HeArt Valve EmboLization and Migration). <i>European Heart Journal</i> , 2019, 40, 3156-3165.	2.2	92
107	Edge-to-Edge Mitral Valve Repair With Extended Clip Arms. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 1356-1365.	2.9	84
108	Transcatheter aortic valve implantation vs. surgical aortic valve replacement for treatment of symptomatic severe aortic stenosis: an updated meta-analysis. <i>European Heart Journal</i> , 2019, 40, 3143-3153.	2.2	297

#	ARTICLE	IF	CITATIONS
109	Mitral regurgitation in heart failure: time for a rethink. <i>European Heart Journal</i> , 2019, 40, 2189-2193.	2.2	38
110	Validation of High-Risk Features for Stent-Related Ischemic Events as Endorsed by the 2017 DAPT Guidelines. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 820-830.	2.9	36
111	Imaging Assessment of Tricuspid Regurgitation Severity. <i>JACC: Cardiovascular Imaging</i> , 2019, 12, 469-490.	5.3	188
112	Long-term outcomes with balloon-expandable and self-expandable prostheses in patients undergoing transfemoral transcatheter aortic valve implantation for severe aortic stenosis. <i>International Journal of Cardiology</i> , 2019, 290, 45-51.	1.7	13
113	Valvular Resistance and Bleeding Events Among Patients Undergoing Transcatheter Aortic Valve Replacement. <i>Structural Heart</i> , 2019, 3, 220-228.	0.6	0
114	Amplatzer patent foramen ovale occluder: safety and efficacy. <i>Expert Review of Medical Devices</i> , 2019, 16, 173-182.	2.8	15
115	Two-year outcomes of the MITRA-FR trial: towards an integrated approach in the evaluation of patients with secondary mitral regurgitation. <i>European Journal of Heart Failure</i> , 2019, 21, 1628-1631.	7.1	1
116	Ischemia and Bleeding in Cancer Patients Undergoing Percutaneous Coronary Intervention. <i>JACC: CardioOncology</i> , 2019, 1, 145-155.	4.0	20
117	Outcomes After Current Transcatheter Tricuspid Valve Intervention. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 155-165.	2.9	246
118	Transcatheter aortic valve replacement in patients with concomitant mitral stenosis. <i>European Heart Journal</i> , 2019, 40, 1342-1351.	2.2	29
119	Percutaneous patent foramen ovale closure during live case demonstrations. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 93, 982-988.	1.7	0
120	Prognostic Value of Right Ventricular Dysfunction on Clinical Outcomes After Transcatheter Aortic Valve Replacement. <i>JACC: Cardiovascular Imaging</i> , 2019, 12, 577-587.	5.3	85
121	Interventional treatment of mitral valve regurgitation: an alternative to surgery?. <i>Swiss Medical Weekly</i> , 2019, 149, w20023.	1.6	3
122	Optimal fluoroscopic viewing angles of right-sided heart structures in patients with tricuspid regurgitation based on multislice computed tomography. <i>EuroIntervention</i> , 2019, 15, .	3.2	5
123	Early versus newer generation devices for transcatheter aortic valve implantation in routine clinical practice: a propensity score matched analysis. <i>Open Heart</i> , 2018, 5, e000695.	2.3	36
124	New-onset arrhythmias following transcatheter aortic valve implantation: a systematic review and meta-analysis. <i>Heart</i> , 2018, 104, 1208-1215.	2.9	34
125	Transatrial implantation of a transcatheter heart valve for severe mitral annular calcification. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2018, 156, 132-142.	0.8	69
126	Transcatheter Tricuspid Valve-in-Valve Intervention for Degenerative Bioprosthetic Tricuspid Valve Disease. <i>Journal of the American Society of Echocardiography</i> , 2018, 31, 491-504.	2.8	14



#	ARTICLE	IF	CITATIONS
127	Transcatheter aortic valve thrombosis: incidence, clinical presentation and long-term outcomes. <i>European Heart Journal Cardiovascular Imaging</i> , 2018, 19, 398-404.	1.2	36
128	Transcatheter Aortic Valve Replacement via the Transcarotid Access. <i>Circulation: Cardiovascular Interventions</i> , 2018, 11, e007459.	3.9	6
129	Comparison between Three-Dimensional Echocardiography and Computed Tomography for Comprehensive Tricuspid Annulus and Valve Assessment in Severe Tricuspid Regurgitation: Implications for Tricuspid Regurgitation Grading and Transcatheter Therapies. <i>Journal of the American Society of Echocardiography</i> , 2018, 31, 1190-1202.e3.	2.8	37
130	Unselected Use of Ultrathin Strut Biodegradable Polymer Sirolimus-Eluting Stent Versus Durable Polymer Everolimus-Eluting Stent for Coronary Revascularization. <i>Circulation: Cardiovascular Interventions</i> , 2018, 11, e006741.	3.9	13
131	Embolic protection for tricuspid valve-in-valve intervention. <i>European Heart Journal</i> , 2018, 39, 1748-1748.	2.2	0
132	Impact of Resting Heart Rate at 30 Days Following Transcatheter or Surgical Aortic Valve Replacement and Cardiovascular Outcomes: Insights from The PARTNER 2 Trial. <i>Structural Heart</i> , 2018, 2, 441-447.	0.6	0
133	Frequency, Reasons, and Impact of Premature Ticagrelor Discontinuation in Patients Undergoing Coronary Revascularization in Routine Clinical Practice. <i>Circulation: Cardiovascular Interventions</i> , 2018, 11, e006132.	3.9	38
134	Fluoroscopic Anatomy of Right-Sided Heart Structures for Transcatheter Interventions. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 1614-1625.	2.9	25
135	Incidence and impact of renal dysfunction on clinical outcomes after transcatheter aortic valve implantation. <i>International Journal of Cardiology</i> , 2018, 250, 73-79.	1.7	11
136	Transfemoral aortic valve implantation of Edwards SAPIEN 3 without predilatation. <i>Catheterization and Cardiovascular Interventions</i> , 2017, 89, E38-E43.	1.7	25
137	Rates and predictors of hospital readmission after transcatheter aortic valve implantation. <i>European Heart Journal</i> , 2017, 38, 2211-2217.	2.2	54
138	The impact of functional vs degenerative mitral regurgitation on clinical outcomes among patients undergoing transcatheter aortic valve implantation. <i>American Heart Journal</i> , 2017, 184, 71-80.	2.7	29
139	Latest evidence on transcatheter aortic valve implantation vs. surgical aortic valve replacement for the treatment of aortic stenosis in high and intermediate-risk patients. <i>Current Opinion in Cardiology</i> , 2017, 32, 117-122.	1.8	12
140	Effects of coronary artery disease in patients undergoing transcatheter aortic valve implantation: A study of age- and gender-matched cohorts. <i>International Journal of Cardiology</i> , 2017, 243, 150-155.	1.7	23
141	Predictors of 1-Year Mortality After Transcatheter Aortic Valve Implantation in Patients With and Without Advanced Chronic Kidney Disease. <i>American Journal of Cardiology</i> , 2017, 120, 2025-2030.	1.6	18
142	Frequency, Timing, and Impact of Access-Site and Non-Access-Site Bleeding on Mortality Among Patients Undergoing Transcatheter Aortic Valve Replacement. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 1436-1446.	2.9	99
143	Transcatheter Tricuspid Valve Repair With a New Transcatheter Coaptation System for the Treatment of Severe Tricuspid Regurgitation. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 1994-2003.	2.9	96
144	Compassionate use of the PASCAL transcatheter mitral valve repair system for patients with severe mitral regurgitation: a multicentre, prospective, observational, first-in-man study. <i>Lancet</i> , 2017, 390, 773-780.	13.7	187

#	ARTICLE	IF	CITATIONS
145	Pitfalls in TAMVI: experience with the repositionable Lotus® Valve System. <i>Journal of Cardiothoracic Surgery</i> , 2017, 12, 47.	1.1	2
146	Prognostic impact of invasive haemodynamic measurements in combination with clinical and echocardiographic characteristics on two-year clinical outcomes of patients undergoing transcatheter aortic valve implantation. <i>EuroIntervention</i> , 2017, 12, e2186-e2193.	3.2	10
147	Second transcatheter closure for residual shunt following percutaneous closure of patent foramen ovale. <i>EuroIntervention</i> , 2017, 13, 858-866.	3.2	15
148	Predictors of Early (1-Week) Outcomes Following Left Atrial Appendage Closure With Amplatzer Devices. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 1374-1383.	2.9	38
149	Transcatheter aortic valve implantation vs. surgical aortic valve replacement for treatment of severe aortic stenosis: a meta-analysis of randomized trials. <i>European Heart Journal</i> , 2016, 37, 3503-3512.	2.2	275
150	Nuss procedure for pectus excavatum in adults: long-term results in a prospective observational study. <i>European Journal of Cardio-thoracic Surgery</i> , 2016, 50, 934-939.	1.4	22
151	Impact of Renal Dysfunction on Results of Transcatheter Aortic Valve Replacement Outcomes in a Large Multicenter Cohort. <i>American Journal of Cardiology</i> , 2016, 118, 1888-1896.	1.6	37
152	Transcatheter Aortic Valve Replacement for the Treatment of Pure Native Aortic Valve Regurgitation. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 2308-2317.	2.9	102
153	External validity of the "all-comers" design: insights from the BIOSCIENCE trial. <i>Clinical Research in Cardiology</i> , 2016, 105, 744-754.	3.3	11
154	Percutaneous Coronary Interventions for the Treatment of Stenoses in Small Coronary Arteries. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 1324-1334.	2.9	63
155	Short-term catheter based treatment of aortic regurgitation by Edwards' Sapien 3 valve-in-valve implantation because of a poorly placed Medtronic CoreValve. <i>International Journal of Cardiology</i> , 2016, 207, 120-121.	1.7	1
156	Post-Operational Troponin Elevation and Clinical Outcomes Following Transcatheter Aortic Valve Implantation. <i>Journal of the American Heart Association</i> , 2016, 5, .	3.7	41
157	Transcatheter aortic valve implantation with the NVT Allegra transcatheter heart valve system: first-in-human experience with a novel self-expanding transcatheter heart valve. <i>EuroIntervention</i> , 2016, 12, 71-77.	3.2	35
158	Effect of resting heart rate on two-year clinical outcomes of high-risk patients with severe symptomatic aortic stenosis undergoing transcatheter aortic valve implantation. <i>EuroIntervention</i> , 2016, 12, 490-498.	3.2	4
159	Bilateral, reversible coronary obstruction during aortic valve-in-valve implantation of a repositionable valve system. <i>EuroIntervention</i> , 2016, 12, 1195-1195.	3.2	2
160	Transcatheter aortic valve implantation today and tomorrow. <i>Swiss Medical Weekly</i> , 2016, 146, w14299.	1.6	5
161	Transcarotid aortic valve-in-valve implantation for degenerated stentless aortic root conduits with severe regurgitation: a case series. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2015, 20, 694-700.	1.1	14
162	Effect of Right Ventricular Function and Tricuspid Regurgitation on Outcomes After Transcatheter Aortic Valve Implantation. <i>Circulation: Cardiovascular Interventions</i> , 2015, 8, .	3.9	4

#	ARTICLE	IF	CITATIONS
163	Expanding Indications of Transcatheter Heart Valve Interventions. JACC: Cardiovascular Interventions, 2015, 8, 1777-1796.	2.9	53
164	Impact of Mitral Regurgitation on Clinical Outcomes of Patients With Low-Ejection Fraction, Low-Gradient Severe Aortic Stenosis Undergoing Transcatheter Aortic Valve Implantation. Circulation: Cardiovascular Interventions, 2015, 8, e001895.	3.9	25
165	Clinical Outcomes and Revascularization Strategies in Patients With Low-Flow, Low-Gradient Severe Aortic Valve Stenosis According to the Assigned Treatment Modality. JACC: Cardiovascular Interventions, 2015, 8, 704-717.	2.9	39
166	Early results of first versus second generation Amplatzer occluders for left atrial appendage closure in patients with atrial fibrillation. Clinical Research in Cardiology, 2015, 104, 656-665.	3.3	66
167	Validation of the Valve Academic Research Consortium Bleeding Definition in Patients With Severe Aortic Stenosis Undergoing Transcatheter Aortic Valve Implantation. Journal of the American Heart Association, 2015, 4, e002135.	3.7	23
168	Effect of Pulmonary Hypertension Hemodynamic Presentation on Clinical Outcomes in Patients With Severe Symptomatic Aortic Valve Stenosis Undergoing Transcatheter Aortic Valve Implantation. Circulation: Cardiovascular Interventions, 2015, 8, e002358.	3.9	107
169	Response To Letter Regarding Article, "Effect of Pulmonary Hypertension Hemodynamic Presentation on Clinical Outcomes in Patients With Severe Symptomatic Aortic Valve Stenosis Undergoing Transcatheter Aortic Valve Implantation: Insights From the New Proposed Pulmonary Hypertension Classification". Circulation: Cardiovascular Interventions, 2015, 8, e003064.	3.9	3
170	Effect of B-type Natriuretic Peptides on Long-Term Outcomes After Transcatheter Aortic Valve Implantation. American Journal of Cardiology, 2015, 116, 1560-1565.	1.6	47
171	Long-term outcome of elderly patients with severe aortic stenosis as a function of treatment modality. Heart, 2015, 101, 30-36.	2.9	26
172	A propensity score-matched comparison between Cardia and Amplatzer PFO closure devices - insights from the SOLUTION registry (Swiss percutaneous patent foramen ovale closure in recurrent clinical) Tj ETQq0 0 0 3gT / Overclock 10 Tf	3.9	10
173	Safety, feasibility, and long-term results of percutaneous closure of atrial septal defects using the Amplatzer septal occluder without periprocedural echocardiography. Journal of Invasive Cardiology, 2015, 27, 157-62.	0.4	10
174	Transcatheter mitral valve implantation (TMVI) using the Edwards FORTIS device. EuroIntervention, 2014, 10, U120-U128.	3.2	85
175	Assessment of low-flow, low-gradient, severe aortic stenosis: an invasive evaluation is required for decision making. EuroIntervention, 2014, 10, U61-U68.	3.2	8
176	Cerebral protection devices for transcatheter aortic valve implantation: is better the enemy of good?. EuroIntervention, 2013, 9, S124-S128.	3.2	13
177	Long-Term Propensity Score-Matched Comparison of Percutaneous Closure of Patent Foramen Ovale With Medical Treatment After Paradoxical Embolism. Circulation, 2012, 125, 803-812.	1.6	160
178	Long-term follow-up after percutaneous closure of patent foramen ovale for secondary prevention of paradoxical embolism in elderly patients (>70 years). European Geriatric Medicine, 2012, 3, 23-27.	2.8	1
179	Accidental closure of the left upper pulmonary vein with an Amplatzer atrial septal defect occluder. Journal of Invasive Cardiology, 2012, 24, E219-21.	0.4	0
180	Assessment of right ventricular systolic function: Comparison between cardiac magnetic resonance derived ejection fraction and pulsed-wave tissue Doppler imaging of the tricuspid annulus. International Journal of Cardiology, 2011, 151, 58-62.	1.7	56

#	ARTICLE	IF	CITATIONS
181	Figulla PFO occluder versus Amplatzer PFO occluder for percutaneous closure of patent foramen ovale. <i>Catheterization and Cardiovascular Interventions</i> , 2011, 77, 709-714.	1.7	18
182	Patent Foramen Ovale May Be Causal for the First Stroke but Unrelated to Subsequent Ischemic Events. <i>Stroke</i> , 2011, 42, 2891-2895.	2.0	26
183	Improvement of migraine headaches after percutaneous closure of patent foramen ovale for secondary prevention of paradoxical embolism. <i>Heart</i> , 2010, 96, 967-973.	2.9	77
184	Percutaneous closure of patent foramen ovale for migraine headaches refractory to medical treatment. <i>Catheterization and Cardiovascular Interventions</i> , 2009, 74, 124-129.	1.7	22
185	Late Results After Percutaneous Closure of Patent Foramen Ovale for Secondary Prevention of Paradoxical Embolism Using the Amplatzer PFO Occluder Without Intraprocedural Echocardiography. <i>JACC: Cardiovascular Interventions</i> , 2009, 2, 116-123.	2.9	77
186	Safety and feasibility of percutaneous closure of patent foramen ovale without intra-procedural echocardiography in 825 patients. <i>Swiss Medical Weekly</i> , 2008, 138, 567-72.	1.6	30
187	Clinical relevance of coronary angiography at the time of percutaneous closure of a patent foramen ovale. <i>Catheterization and Cardiovascular Interventions</i> , 2007, 70, 641-645.	1.7	10
188	A case of myocardial infarction with conduction abnormalities. <i>Cardiovascular Medicine(Switzerland)</i> , 0, , .	0.0	0